Could the anti-cancer gene p53 be a target in treating kidney cancer?

nephrons
A Sidney Kimmel team is planning further studies to identify treatments that might be able to activate the tumor suppressor p53 in kidney cancer patients with PBRM1 mutations. (Lindstrom et al./CC-BY 4.0)

Mutations in the gene p53 are thought to cause more than half of all cancers, but the gene has not been associated with kidney cancer—until now.

Scientists at Sidney Kimmel Cancer Center – Jefferson Health discovered that one of the most commonly mutated genes in kidney cancer, PBRM1, binds to the activated form of p53 in a specific spot. Disruptions to that process can mutate PBRM1, causing it to lose its ability to hold back cancer, they discovered. They published the finding in the journal Nature Communications.

The Sidney Kimmel team made the discovery by testing tumor samples from mice and humans to determine how PBRM1 can act as a “reader” of the activated p53 protein, meaning it translates the p53 gene’s tumor-suppressing instructions. They discovered that the translation happens within a specific chemical marker known as an acetyl group and that tumor-derived mutations at one particular spot can disrupt that process.

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

Study co-author Haifeng Yang, Ph.D., a researcher at Sidney Kimmel, believes the findings suggest a therapeutic window for activating the p53 pathway in patients with PBRM1 deficiencies. 

RELATED: Unlocking a secret of the anti-cancer gene p53

Biotech companies developing new treatments for kidney cancer have seen their fair share of disappointments lately. In November, the FDA sent Aveo Oncology back to the drawing board on its VEGF inhibitor, tivozanib, in kidney cancer. AstraZeneca scrapped development of phase 3 MET inhibitor savolitinib in renal cell carcinoma in October. And Immunicum turned in disappointing data from a trial comparing its dendritic cell vaccine ilixadencel to Pfizer’s Sutent in metastatic renal cell carcinoma.

Still, there is plenty of excitement for some new approaches that are showing promise in kidney cancer. In May, Merck handed over $1.1 billion for Peloton, a company in late-stage trials of an HIF-2α inhibitor in metastatic kidney cancer. In a phase 2 trial, the drug produced a clinical benefit in 78% of patients who had previously been treated with a checkpoint inhibitor such as Merck’s Keytruda.

Yang’s team at Sidney Kimmel is planning further studies to identify drugs or combination treatments that might be able to activate p53 in kidney cancer patients with PBRM1 mutations.

Mutations in PBRM1 didn’t completely destroy p53’s functioning and therefore are unlikely to be associated with high-grade or aggressive kidney tumors, the Sidney Kimmel team noted in their study. That said, “a partially disabled p53 pathway may still be important for … tumor growth, and this could have therapeutic implications for modulating the p53 pathway to treat [kidney cancer] patients.”

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.